PG/PK/PD study of irinotecan and its application in the treatment of malignant tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500111380

Enrollment

Unknown

Registered

2025-10-30

Start date

2025-11-01

Completion date

Unknown

Last updated

2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer, lung cancer

Interventions

Elinotecan medication group:None

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients who are using irinotecan for the first time; 2.Monitor blood drug concentration according to medical advice during chemotherapy; 3.Chemotherapy is effective and can complete all treatment courses.

Exclusion criteria

Exclusion criteria: 1.Patients with previous liver and kidney dysfunction; 2.Data with poor compliance and inaccurate laboratory results; 3.Patients with severe adverse drug reactions who terminate treatment; 4.Patients with incomplete information.

Design outcomes

Primary

Measure	Time frame
blood drug concentration;	—

Countries

China

Contacts

Public ContactLina You

Yan'An Hospital of Kunming City

youlinakm@126.com+86 871 6321 1154

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026